⌘K
t
Arecor Therapeutics plc announced the appointment of Singer Capital Markets Advisory LLP as its Nominated Advisor and Joint Broker. This change took effect immediately on 9 January 2025.
| Date | 9 Jan 2025 |
| Time | 07:00:06 |
| Category | Corporate updates |
| ID | 6601S |
Arecor Therapeutics plc
("Arecor" or the "Group")
CHANGE OF NOMINATED ADVISOR AND JOINT BROKER
Cambridge, UK, 9 January 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Singer Capital Markets Advisory LLP has been appointed as the Company's Nominated Advisor and Joint Broker with immediate effect.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
www.arecor.com |
|
Dr Sarah Howell, Chief Executive Officer David Ellam, Interim Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
Singer Capital Markets Advisory LLP (NOMAD and Joint Broker) Phil Davies, Sam Butcher |
Tel : +44 (0) 20 7496 3000 |
|
WG Partners LLP (Joint Broker) |
|
|
Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
|
|
|
|
ICR Healthcare |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com